
Polyphor AG bags funding for murepavadin
Swiss Polyphor AG (Allschwil) is developing its lead Outer Membrane Protein Targeting Antibiotic (OMPTA) candidate inhaled murepavadin against...

Germany first EU country to launch COVID-19 therapy offensive?
"Besides protection by masks, social distancing etc, rapid diagnostic testing, and COVID-19 vaccines, we are now establishing a fourth pillar of...

Roche licences antiviral nucleoside from Atea
Under the agreement, Roche will pay US$350m in cash for ex US-distribution of Atea Pharmaceuticals antiviral Phase II candidate. Atea has the option...

How microplastic particles get into the body
Microplastic particles exposed to freshwater or saltwater environments for several weeks are about ten times more likely than pristine particles to...

Valneva in talks with EU about 60 million vaccine doses
VLA2001 is currently the only inactivated vaccine candidate in clinical trials against COVID-19 in Europe. The vaccine candidate entered Phase I/II...

Drug set to rescue COVID-19 patients at ICUs
Initial data from an US expanded access (EA) use of RLF-100™ (aviptadil) in 90 ICU patients with critical COVID-19 and severe comorbidities...

Biotech companies launch Biotech Austria
According to Apeiron CEO and Biotech Austria founding president Peter LLewellyn-Davies, Austria's vibrant biotech sector needs a voice that can be...